Aarti Drugs Ltd (BOM:524348)

₹ 471.1 47.15 (11.12%) Market Cap: 43.00 Bil Enterprise Value: 48.61 Bil PE Ratio: 28.41 PB Ratio: 3.37 GF Score: 89/100

Q2 2025 Aarti Drugs Ltd Earnings Call Transcript
Oct 25, 2024

₹475.05 (-2.01%)

Earnings
Q1 2025 Aarti Drugs Ltd Earnings Call Transcript
Jul 29, 2024

₹503.25 (-4.41%)

Earnings
Q3 2024 Aarti Drugs Ltd Earnings Call Transcript
Jan 25, 2024

₹503.9 (-5.77%)

Earnings
Q2 2024 Aarti Drugs Ltd Earnings Call Transcript
Oct 20, 2023

₹518.55 (-4.83%)

Earnings
Q1 2024 Aarti Drugs Ltd Earnings Call Transcript
Jul 24, 2023

₹605.65 (+18.62%)

Earnings
Q4 2023 Aarti Drugs Ltd Earnings Call Transcript
May 02, 2023

₹457.7 (+8.74%)

Earnings
Q3 2023 Aarti Drugs Ltd Earnings Call Transcript
Jan 30, 2023

₹401.9 (-2.11%)

Earnings
Q2 2023 Aarti Drugs Ltd Earnings Call Transcript
Oct 21, 2022

₹461.35 (+0.07%)

Earnings
Q1 2023 Aarti Drugs Ltd Earnings Call Transcript
Jul 28, 2022

₹405.85 (-3.09%)

Earnings
Q4 2022 Aarti Drugs Ltd Earnings Call Transcript
May 10, 2022

₹426.25 (-3.18%)

Earnings
Q3 2022 Aarti Drugs Ltd Earnings Call Transcript
Feb 02, 2022

₹512.9 (+2.02%)

Earnings
Q2 2022 Aarti Drugs Ltd Earnings Call Transcript
Oct 28, 2021

₹591.95 (-4.88%)

Earnings
Q1 2022 Aarti Drugs Ltd Earnings Call Transcript
Jul 27, 2021

₹719.9 (-0.37%)

Earnings
Q4 2021 Aarti Drugs Ltd Earnings Call Transcript
May 17, 2021

₹752 (-8.05%)

Earnings
Q3 2021 Aarti Drugs Ltd Earnings Call Transcript
Jan 27, 2021

₹695.6 (-3.05%)

Earnings
Q2 2021 Aarti Drugs Ltd Earnings Call Transcript
Oct 26, 2020

₹711.35 (-4.99%)

Earnings
Q1 2021 Aarti Drugs Ltd Earnings Call Transcript
Jul 27, 2020

₹436.79 (+9.87%)

Earnings
Q4 2020 Aarti Drugs Ltd Earnings Call Transcript
May 18, 2020

Earnings

Q3 2022 Aarti Drugs Ltd Earnings Call Transcript

Feb 02, 2022 / 05:30AM GMT

Release Date Price: ₹512.9 (+2.02%)

Transcript

Operator

Ladies and gentlemen, good day, and welcome to Aarti Drugs Limited Q3 FY22 earnings conference call. This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions, and expectations of the company as in the date of this call. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Adhish Patil, Chief Financial Officer at Aarti Drugs Limited. Thank you, and over to you, sir.

Adhish Patil

Aarti Drugs Limited - CFO

Thank you. Good morning, everyone, and thank you for joining us today to discuss our financial results for the quarter ended December 31, 2021. At the onset, I hope everyone is healthy, safe, and taking all the necessary caution in the wake of the third wave of COVID-19.

Before I take you through the performance highlights, allow me to remind you that as communicated in the earlier earnings call,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.